Se estima que 7,1 millones de niños (11,4% de los menores de 3 a 17 años) han recibido un diagnóstico de TDAH en Estados Unidos, mientras que el aumento de casos en adultos ha transformado la psiquiatría ambulatoria. Al mismo tiempo, los límites federales de fabricación y los cuellos de botella en la distribución mantienen desabastecidas a farmacias en 48 estados. Los siguientes datos provienen de los Centers for Disease Control and Prevention (CDC), la base de escasez de la FDA, la DEA, el IQVIA Institute y SAMHSA.
Este escenario clínico se relaciona estrechamente con la demanda en campus mental health services, el bienestar reflejado en student mental health y el uso de mental health apps.
TL;DR
- 11,4% de los niños en EE. UU. (7,1 millones) han sido diagnosticados con TDAH (CDC NSCH).
- 61,5% de los niños con TDAH toman medicamentos recetados para el control de síntomas (CDC).
- Las recetas de estimulantes para adultos (20-39 años) aumentaron un 45,1% en cinco años (IQVIA).
- El 76% de las farmacias comunitarias sufren escasez continua de fármacos estimulantes (ASHP).
- Los diagnósticos en mujeres adultas crecieron un 84% entre 2018 y 2025 (CDC / Epic Health Research).
- Las cuotas de la DEA para anfetaminas limitan la producción a unos 45.000 kg de principio activo (DEA).
- Las consultas por telemedicina representaron el 38,2% de las evaluaciones iniciales de adultos en 2025 (SAMHSA).
- Más de $185.000 millones de dólares anuales es el costo económico del TDAH en EE. UU. (J. of Clinical Psychiatry).
- Los niños presentan una prevalencia del 14,5%, frente al 8,0% en niñas en edad escolar (CDC).
- El 53,6% de los menores diagnosticados recibe terapia conductual o adaptaciones escolares (CDC NSCH).
- El desabastecimiento de lisdexanfetamina genérica afectó al 62% de las farmacias tras perder la patente (FDA).
- El 18,4% de los adultos con TDAH reportan ajustes laborales debido a síntomas no tratados (CHADD).
1. Prevalence and Diagnostic Trajectories
Las tasas de diagnóstico de TDAH han aumentado de forma sostenida a lo largo de dos décadas, como consecuencia de criterios clínicos más precisos y una mayor detección en etapas tardías.
| Demographic Cohort | ADHD Prevalence Rate (%) | Estimated Patient Count | 10-Year Trajectory Trend |
|---|---|---|---|
| Children Aged 3-17 (Total) | 11.4% | 7.10 Million | +18.8% Relative Growth |
| Male Youth (Aged 3-17) | 14.5% | 4.62 Million | +12.4% Relative Growth |
| Female Youth (Aged 3-17) | 8.0% | 2.48 Million | +33.3% Relative Growth |
| Adolescents (Aged 12-17) | 13.2% | 3.41 Million | +14.8% Relative Growth |
| Adults Aged 18-44 | 5.4% | 5.65 Million | +74.2% Relative Growth |
| Adults Aged 45 and Older | 2.1% | 2.68 Million | +42.1% Relative Growth |
Source: CDC National Survey of Children’s Health (NSCH) and National Health Interview Survey.
2. Prescription Volumes and Treatment Modalities
El abordaje farmacológico sigue siendo la opción terapéutica predominante en cuadros moderados a severos, complementándose con intervenciones conductuales en el ámbito escolar y familiar.
| Therapeutic Treatment Category | Share of Diagnosed Patients | Annual Prescriptions Dispensed | Primary Formulation Type |
|---|---|---|---|
| Mixed Amphetamine Salts (Adderall / XR) | 38.2% | 29.4 Million Rx | Short & Long-Acting Stimulant |
| Lisdexamfetamine Dimesylate (Vyvanse) | 27.4% | 21.1 Million Rx | Prodrug Long-Acting Stimulant |
| Methylphenidate (Ritalin / Concerta) | 22.1% | 17.0 Million Rx | Short & Osmotic Release Stimulant |
| Non-Stimulants (Atomoxetine, Guanfacine, Clonidine) | 12.3% | 9.5 Million Rx | SNRI / Alpha-2 Agonists |
| Behavioral Counseling Alone (No Rx) | 18.2% | N/A (Non-Pharm) | Psychosocial Support |
| Combined Medication & Behavioral Therapy | 31.5% | N/A (Multi-Modal) | Integrated Care Standard |
Source: IQVIA National Prescription Audit and CDC treatment pattern analyses.
3. The National Stimulant Supply Shortage
Desde finales de 2022, las demoras en la cadena de suministros y las estrictas restricciones impuestas por las cuotas de fabricación federales han provocado quiebres de stock recurrentes en farmacias de todo el país.
| Shortage Metric / Indicator | Value / Rate | Regulatory Context | Tracking Agency |
|---|---|---|---|
| Pharmacies Reporting Active Stimulant Stockouts | 76.4% | Independent & Health System Sites | ASHP Drug Shortage Survey |
| Average Prescription Refill Delay Time | 12.8 Days | From Normal 24h Processing | Patient Advocacy Surveys |
| Patients Forcibly Switched to Alternate Formulations | 42.1% | Due to Local Out-of-Stock Status | CHADD Patient Tracker |
| Manufacturers Operating at 100% DEA Quota Limit | 84.0% | Cannot Exceed Allocated Ceiling | DEA / FDA Joint Letters |
| Unused DEA Quotas Returned by Inactive Producers | 1.1B Doses (Historical) | Logistical Allocation Inefficiencies | Senate Finance Committee |
Source: FDA Drug Shortages Database and ASHP Clinical Bulletins.
4. Telehealth Expansion and Digital Diagnosis
La flexibilización de los requisitos presenciales de la Ley Ryan Haight potenció el uso de consultas virtuales para la evaluación y seguimiento de pacientes con dificultades de concentración.
| Telehealth Dimension | Metric Value | Comparative Pre-2020 Baseline | Data Source Authority |
|---|---|---|---|
| Adult ADHD Initial Consultations via Telehealth | 38.2% | < 2.0% Pre-Pandemic | SAMHSA Behavioral Tracker |
| Average Wait Time for Virtual Evaluation | 9.4 Days | 48.2 Days (In-Person Clinic) | Fair Health / KFF |
| Clinicians Continuing Remote Controlled Substance Rx | 64.2% | Subject to DEA Flexibilities | American Psychiatric Assoc. |
| Follow-up Compliance via Telehealth Modalities | 78.4% | 62.1% In-Person Benchmark | Journal of Medical Internet Res. |
| DEA Extensions of Remote Prescribing Flexibilities | Active through late 2026 | Rulemaking in Progress | Federal Register Announcements |
Source: KFF Telehealth Tracking Briefs and American Psychiatric Association clinician surveys.
5. Economic Burden, Workplace Impact, and Education Accommodations
El coste socioeconómico del TDAH abarca los apoyos educativos contemplados en la Sección 504 de la ley educativa estadounidense y la merma de rendimiento laboral debida a dificultades de planificación ejecutiva.
| Socioeconomic Impact Metric | Estimated Annual Value | Context / Methodology | Research Authority |
|---|---|---|---|
| Total Annual US Economic Burden of ADHD | ”$185.2 Billion” | Direct Healthcare & Societal Loss | J. of Clinical Psychiatry |
| Annual Excess Direct Healthcare Cost per Patient | ”$3,120” | Adjusted for Matched Controls | Health Care Cost Institute |
| K-12 Students with ADHD on 504 / IEP Plans | 68.4% | Public Elementary & Secondary | Dept of Education OCR |
| Adults Reporting Workplace Burnout or Job Change | 34.2% | Attributed to Executive Dysfunction | ADDitude Workplace Survey |
| Untreated Adult Productivity Loss per Worker | ”$4,350 Annually” | Absenteeism & Presenteeism | WHO Health & Work Performance |
Source: Journal of Clinical Psychiatry Economic Analyses and US Department of Education OCR.
Summary: ADHD Diagnosis and Prescriptions by the Numbers
| Clinical & Pharmaceutical Indicator | Value / Metric | Source Authority |
|---|---|---|
| US Children Diagnosed with ADHD (Ages 3-17) | 7.10 Million (11.4%) | CDC NSCH |
| Diagnosed Children Receiving Prescription Medication | 61.5% (~4.37M) | CDC NSCH |
| Diagnosed Children Receiving Behavioral Therapy | 53.6% | CDC NSCH |
| Five-Year Growth in Adult Stimulant Prescriptions | +45.1% | IQVIA Institute |
| Pharmacies Experiencing Ongoing Stimulant Stockouts | 76.4% | ASHP |
| Adult Female ADHD Diagnosis Growth (2018-2025) | +84.0% | Epic Health / CDC |
| Male vs Female Diagnosis Ratio in Youth | 1.81 to 1 (14.5% vs 8.0%) | CDC NSCH |
| Total Annual Prescriptions for Mixed Amphetamine Salts | 29.4 Million Rx | IQVIA |
| Total Annual Prescriptions for Lisdexamfetamine | 21.1 Million Rx | IQVIA |
| Share of Adult ADHD Consultations via Telehealth | 38.2% | SAMHSA |
| Average Refill Delay During Active Supply Shortage | 12.8 Days | ASHP / Advocacy |
| Total Annual US Societal & Healthcare Cost | $185.2 Billion | J. Clinical Psych. |
| K-12 Diagnosed Students Receiving 504 / IEP Support | 68.4% | US Dept of Education |
| Excess Annual Healthcare Expenditure per Patient | $3,120 | HCCI Benchmarks |
| Adults Reporting Job Adjustments Due to Symptoms | 34.2% | CHADD Surveys |
| DEA Controlled Substance Quota Volume (Amphetamines) | ~45,000 kg API | DEA Federal Register |
Methodology and Sources
Surveillance estimates derived from epidemiologic registries compiled by the Centers for Disease Control and Prevention (CDC), drug tracking records from the FDA Drug Shortages Database, and commercial dispensing audits from the IQVIA Institute.
-
CDC National Survey of Children’s Health (NSCH): Diagnostic Prevalence and Treatment Interventions.
-
FDA Drug Shortages Database and American Society of Health-System Pharmacists (ASHP) Drug Shortage Bulletins.
-
Drug Enforcement Administration (DEA) Established Aggregate Production Quotas for Schedule II Controlled Substances.
-
IQVIA Institute for Human Data Science: National Prescription Audit and Medicines Use in the U.S.
-
Substance Abuse and Mental Health Services Administration (SAMHSA): National Survey on Drug Use and Health.
-
Journal of Clinical Psychiatry: The Societal and Economic Costs of ADHD in the United States.
-
Data watch: Survey-based childhood diagnosis estimates rely on parental recall and formal clinical confirmation, which can produce modest variances relative to claims-based electronic health record (EHR) studies. Telehealth prescription shares reflect evolving federal regulatory waivers under DEA temporary rules.
Last updated: September 7, 2026. Quarterly updates track ongoing regulatory revisions, pharmaceutical manufacturing releases, and CDC epidemiological reports.